// App-Quantinova.ai

1633 : An Open-Label, Phase 1 Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with CD22-Positive B-Cell Non-Hodgkin's Lymphoma: Preliminary Safety and Efficacy Data

Researchers

Presenter

  • Kiyohiko Hatake

Principal Investigators

  • Andrew Davies

  • David A Macdonald

  • Michael Crump

  • Kensei Tobinai

  • Mitchell R Smith

  • Fritz Offner

  • Shaw-Ling Wang

  • Taro Ishibashi

  • Luisa Paccagnella

  • Erik Vandendries

Medical Centers

  • Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Aichi, Japan

  • Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada

  • Ghent University Hospital, Ghent, Belgium

  • Biostatistics, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada

  • Department of Hematology and Oncology, Cancer Institute Hospital, Japanese Foundation For Cancer Research, Tokyo, Japan

  • National Cancer Center Hospital, Tokyo, Japan

  • University of Southampton Faculty of Medicine, Southampton, United Kingdom

Locations

  • Canada

  • Japan

  • Belgium

  • United Kingdom

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • B-Cell Non-Hodgkin Lymphoma

  • Diffuse large B-cell lymphoma

  • Non-Hodgkin's Lymphoma

  • Mantle cell lymphoma

  • Follicular lymphoma

  • Hodgkin's Lymphoma

  • Thrombocytopenia

  • B cell lymphomas

  • Constipation

  • Non‐Hodgkin Lymphoma

  • Neutropenia

  • Lymphocytopenia

  • Lymphomas

Biomarkers

  • Alanine transaminase

  • Aspartate aminotransferase

Drug/Treatment

  • Filgrastim

  • Inotuzumab ozogamicin

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • LL-33288

  • Vincristine

  • Prednisone

  • Rituximab

Outcome

  • N/A

Study Design

  • open label

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved